4.7 Review

The immune response during acute HIV-1 infection: clues for vaccine development

Journal

NATURE REVIEWS IMMUNOLOGY
Volume 10, Issue 1, Pages 11-23

Publisher

NATURE RESEARCH
DOI: 10.1038/nri2674

Keywords

-

Categories

Funding

  1. Center for HIV/AIDS Vaccine Immunology (CHAVI) [A1067854-03]
  2. Medical Research Human Immunology Unit
  3. National Institute for Health Research
  4. Oxford Biomedical Research Centre
  5. Bill and Melinda Gates Foundation [38643, 37874, 38619]
  6. US National Institutes of Health [RO1AI052779, U19AI067854, AI068618, AI64518]
  7. Medical Research Council [MC_U137884177] Funding Source: researchfish
  8. NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [UM1AI068618, U01AI068618, P30AI064518, R01AI052779, U19AI067854] Funding Source: NIH RePORTER
  9. MRC [MC_U137884177] Funding Source: UKRI

Ask authors/readers for more resources

The early immune response to HIV-1 infection is likely to be an important factor in determining the clinical course of disease. Recent data indicate that the HIV-1 quasispecies that arise following a mucosal infection are usually derived from a single transmitted virus. Moreover, the finding that the first effective immune responses drive the selection of virus escape mutations provides insight into the earliest immune responses against the transmitted virus and their contributions to the control of acute viraemia. Strong innate and adaptive immune responses occur subsequently but they are too late to eliminate the infection. In this Review, we discuss recent studies on the kinetics and quality of early immune responses to HIV-1 and their implications for developing a successful preventive HIV-1 vaccine.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available